Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from ...
Introduction Epidemiology Pancreatic adenocarcinoma (PDAC) is the 10th most common cancer but the 3rd deadliest cancer affecting an estimated 64,050 new patients in 2023.1 Incidence rates have continued to rise by approximately 1% every year since 2000 …